Teacher Retirement System of Texas Lowers Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Teacher Retirement System of Texas lowered its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 10.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,358 shares of the company’s stock after selling 1,190 shares during the quarter. Teacher Retirement System of Texas’ holdings in Amphastar Pharmaceuticals were worth $300,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new position in Amphastar Pharmaceuticals in the 4th quarter worth $38,000. Tower Research Capital LLC TRC raised its position in Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company’s stock worth $43,000 after purchasing an additional 348 shares during the period. GAMMA Investing LLC raised its position in Amphastar Pharmaceuticals by 46.6% in the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock worth $39,000 after purchasing an additional 424 shares during the period. Huntington National Bank raised its position in Amphastar Pharmaceuticals by 36.9% in the 4th quarter. Huntington National Bank now owns 1,340 shares of the company’s stock worth $50,000 after purchasing an additional 361 shares during the period. Finally, TD Private Client Wealth LLC raised its position in Amphastar Pharmaceuticals by 22.7% in the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock worth $78,000 after purchasing an additional 388 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Down 5.0%

Shares of AMPH opened at $20.62 on Friday. The firm’s 50-day moving average price is $24.23 and its 200-day moving average price is $27.79. The firm has a market capitalization of $972.01 million, a price-to-earnings ratio of 7.47, a PEG ratio of 5.65 and a beta of 0.72. The company has a current ratio of 2.95, a quick ratio of 2.02 and a debt-to-equity ratio of 0.80. Amphastar Pharmaceuticals, Inc. has a 1-year low of $20.43 and a 1-year high of $53.96.

Analyst Ratings Changes

A number of research firms have issued reports on AMPH. JPMorgan Chase & Co. restated a “neutral” rating and issued a $30.00 price objective (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Wells Fargo & Company decreased their price objective on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, May 8th. Finally, Piper Sandler decreased their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research report on Friday, March 21st. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $32.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.